Karolinska Institutet

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

Stratipath collaborates with Roche to distribute Stratipath Breast, an AI-based solution for breast cancer risk stratification, integrated with Roche’s navify® Digital Pathology software, offering faster, cost-effective alternatives to traditional molecular tests.

RER-CTO, led by the University of Oslo and Karolinska Institutet's Eleni Aklillu, aims to enhance the capacity of Ethiopia and Tanzania's regulatory and ethics committees over three years, focusing on legal frameworks, oversight, and collaboration to align with global best practices in clinical trial oversight.

A drug used for Alzheimer's may slow Lewy body dementia progression, according to research from Karolinska Institutet. Cholinesterase inhibitors (ChEIs) like donepezil, rivastigmine, and galantamine, which prevent the breakdown of acetylcholine, showed significant cognitive decline slowing in Lewy body dementia patients compared to memantine. ChEIs also reduced the risk of death within the first year of diagnosis by 34%.

The Gordon Research Conference on Systems Aging 2022, chaired by Vadim Gladyshev and Steve Horvath, brought together leading scientists to discuss unpublished research on aging, rejuvenation, and longevity interventions. Highlights included talks on epigenetic reprogramming, aging clocks, and AI in aging research, with a focus on fostering collaboration and innovation in a confidential setting.

Mattias Rantalainen leads the Predictive Medicine group at Karolinska Institutet, focusing on AI, machine learning, and big data in medical research, particularly computational pathology. His work aims to improve cancer precision medicine through predictive modeling and patient stratification, supported by various grants and collaborations.

High-dose glucocorticoids remain first-line treatment for idiopathic inflammatory myopathies (IIMs), with immunosuppressants recommended early to control disease and reduce side effects. Combining pharmacological treatment with exercise improves outcomes. Rituximab shows promise for certain autoantibody-positive patients, while other biologics are under investigation. Subgrouping patients may help tailor treatments.

Immunocompromised patients, especially transplant recipients, face high risks from various viral infections, including CMV, HSV, EBV, and HHV-6. Advances in diagnostics have identified emerging viruses and vaccine-preventable diseases causing significant morbidity. The article reviews clinical manifestations, diagnosis, and antiviral therapies for these infections in transplant populations.